Next Article in Journal
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma
Previous Article in Journal
Influence of Trace Elements on Neurodegenerative Diseases of The Eye—The Glaucoma Model
Previous Article in Special Issue
Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti–PD-1 Treatment Efficacy in Urothelial Carcinoma
Review

Pharmacologic Control of CAR T Cells

1
Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, 0379 Oslo, Norway
2
Center for Cancer Cell Reprogramming (CanCell), Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0379 Oslo, Norway
3
Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0379 Oslo, Norway
4
Section for Biochemistry and Molecular Biology, Faculty of Mathematics and Natural Sciences, University of Oslo, 0379 Oslo, Norway
*
Author to whom correspondence should be addressed.
Academic Editor: Pascal Gélébart
Int. J. Mol. Sci. 2021, 22(9), 4320; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094320
Received: 31 March 2021 / Revised: 16 April 2021 / Accepted: 19 April 2021 / Published: 21 April 2021
(This article belongs to the Special Issue Immunotherapy for Hematological and Solid Cancers)
Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors. However, despite these encouraging results, CAR treatment has also been found to lead to serious side effects and capricious response profiles in patients. In addition, the CD19 CAR success has been difficult to reproduce for other types of malignancy. The appearance of resistant tumor variants, the lack of antigen specificity, and the occurrence of severe adverse effects due to over-stimulation of the therapeutic cells have been identified as the major impediments. This has motivated a growing interest in developing strategies to overcome these hurdles through CAR control. Among them, the combination of small molecules and approved drugs with CAR T cells has been investigated. These have been exploited to induce a synergistic anti-cancer effect but also to control the presence of the CAR T cells or tune the therapeutic activity. In the present review, we discuss opportunistic and rational approaches involving drugs featuring anti-cancer efficacy and CAR-adjustable effect. View Full-Text
Keywords: chimeric antigen receptor; small molecules; drugs; kinase inhibitors; CAR T cell; immunotherapy chimeric antigen receptor; small molecules; drugs; kinase inhibitors; CAR T cell; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Caulier, B.; Enserink, J.M.; Wälchli, S. Pharmacologic Control of CAR T Cells. Int. J. Mol. Sci. 2021, 22, 4320. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094320

AMA Style

Caulier B, Enserink JM, Wälchli S. Pharmacologic Control of CAR T Cells. International Journal of Molecular Sciences. 2021; 22(9):4320. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094320

Chicago/Turabian Style

Caulier, Benjamin, Jorrit M. Enserink, and Sébastien Wälchli. 2021. "Pharmacologic Control of CAR T Cells" International Journal of Molecular Sciences 22, no. 9: 4320. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094320

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop